Description

KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C37H56F3N11O11—-[1]Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.—-887.90–99.76–NC(CC[C@@H](C(N)=O)NC([C@H](C(C)C)NC([C@H](CO)NC([C@H](CCCNC(N)=N)NC([C@H](CC1=CC=CC=C1)NC([C@H]2N(CCC2)C(C)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O–Cancer–H2O : 9.09 mg/mL (ultrasonic)–Kallikrein—-Immunology/Inflammation–Peptides